Government Alzheimer plans

Alzheimer's Disease International supports the creation of high-level governmental plans to deal with the large and growing impact of dementia worldwide. Unlike international initiatives, these plans are capable of addressing the problem using a system tailored to the unique culture and demographics of each country.

Government dementia plans can promote the creation of infrastructure and accountability necessary to build dementia-capable programmes for the growing number of people with the disease.

A comprehensive government plan to address the needs of people with dementia provides a mechanism to consider collectively a range of issues including:

  • Promoting broad public awareness of Alzheimer’s and combating stigma
  • Identifying dementia capable support services at all stages of the disease
  • Quantifying the number of individuals with dementia
  • Assessing and improving the quality of health care, social care and long-term care support and services
  • Assessing availability and access to diagnostic services
  • Public health efforts to conduct surveillance and promote brain health

The creation of national and local plans published to date has involved government agencies, legislators, residential and community care providers, professional and family carers, researchers and physicians, and people with dementia.

What is the difference between a 'National Dementia Strategy' and a 'National Governmental Plan'?

Many of these documents on this site carry the word “strategy” in their title, which causes confusion.  ADI defines national dementia strategies as documents generated by private non-governmental groups (many times with governments participating) that can serve as the case statement to persuade governments to create a national or sub national governmental plan.  

A government dementia plan is a policy; a national or sub-national government holding itself accountable for the accomplishment of specific objectives and policy changes, even if objectives are accomplished with non governmental  collaborators.

Reports

Our report, ‘Improving Dementia Care Worldwide’ (PDF), reviews existing national dementia plans from around the world, and puts forward recommendations for governments on what a best practice plan should include and how it should be developed and implemented. The report was commissioned by ADI and Bupa, and written by Prof Anne Margriet Pot and Dr Ionela Petrea from the Netherlands Institute of Mental Health and Addiction (Trimbos-institute). The report is also available in Spanish, French and Portuguese.

An earlier overview, published in April 2012, is available in National Alzheimer and Dementia Plans Planned Policies and Activities (PDF).

We have produced a National Plans Bibliography (PDF), including references to papers discussing developing, implementing and review of national plans.

National Alzheimer plans

The links below will bring you to a page about each country's plan, including where possible some analysis by ADI, and any available reports on the plan implementation.

National Alzheimer Strategies

Sub-national Alzheimer plans

In many countries, sub-national plans by region, province, state or canton are also in development because they are the most appropriate level of government to plan strategically to meet the growing impact, especially as many national governments are increasingly decentralizing to their sub national units for health care and public health planning.

Non-governmental dementia strategies

National dementia strategies are documents generated by private non governmental groups that can serve as the case statement to persuade governments to create a national or sub national governmental plan.

Action in Europe

Alzheimer Europe and associations in Europe have achieved policy action in Europe.

Action in the Americas

The Pan-American Health Organisation published the first Regional Plan of Action on Dementia in October 2015.

The PAHO Regional Plan of Action on Dementia obliges countries to develop national dementia plans, including the promotion of risk reduction strategies through public health programmes, ensuring a rights-based approach to the provision of care and support for people living with dementia and better training for health professionals, as well as more funding for research.

Acknowledgements

Funding to track the progress of national Alzheimer plans and provide the information on this website was provided by the Alzheimer’s Immunotherapy Program of Janssen Alzheimer Immunotherapy and Pfizer Inc.